
|Videos|June 6, 2017
Dr. Hayes on the Future of Biomarkers for Breast Cancer
Author(s)Daniel F. Hayes, MD
Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.
Advertisement
Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.
It is important to determine better ways to identify which patients after 5 years of endocrine-therapy should continue it or switch to another form of therapy, explains Hayes.
According to Hayes, liquid biopsies are exciting and might have a role in determining which patients should be left on their current treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































